Physician profile
Oluchi C Oke
NPI 1124463211
$1,714.71
in general payments reported to CMS, 2019-2025
12 companies · $476 in 2025
The $476 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.25 · 2020: $43.78 · 2021: $128 · 2022: $586 · 2023: $267 · 2024: $178 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883 · Education: $37.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.92 |
| Education | $37.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $585.85 | 2023-2025 | Datroway, Enhertu, Lynparza |
| Genentech USA, INC. | $350.38 | 2021-2022 | |
| Lilly USA, LLC | $239.24 | 2022 | |
| Daiichi Sankyo INC. | $136.49 | 2020-2025 | Enhertu |
| Seagen INC. | $124.72 | 2022 | |
| Puma Biotechnology, INC. | $124.48 | 2025 | |
| Gilead Sciences, INC. | $71.78 | 2024-2025 | Trodelvy |
| Pfizer INC. | $25.00 | 2023 | |
| Emd Serono, INC. | $21.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.52 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oluchi Oke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.